AFLAC (AFL) Stock Analysis – A Brief Overview

By Tamara Parker • Thursday, August 07 10:07 • Permanent Link

Join us for a quick overview of AFLAC, a Diversified Insurance company whose shares moved 0.6% today. Here are some facts about the stock that should help you see the bigger picture:

AFLAC has moved 1.4% over the last year, and the S&P 500 logged a change of 19.3%
AFL has an average analyst rating of hold and is -3.88% away from its mean target price of $107.08 per share
Its trailing earnings per share (EPS) is $4.44
AFLAC has a trailing 12 month Price to Earnings (P/E) ratio of 23.2 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $7.17 and its forward P/E ratio is 14.4
The company has a Price to Book (P/B) ratio of 5.14 in contrast to the S&P 500's average ratio of 4.74
AFLAC is part of the Finance sector, which has an average P/E ratio of 15.92 and an average P/B of 1.78
AFL has reported YOY quarterly earnings growth of -64.2% and gross profit margins of 0.4%
The company has a free cash flow of $6.07 Billion, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Aflac Incorporated, through its subsidiaries, provides supplemental health and life insurance products. The company operates in two segments, Aflac Japan and Aflac U.S. The Aflac Japan segment offers cancer, medical, nursing care, whole life, and GIFT insurance products, as well as WAYS and child endowment, and Tsumitasu insurance products in Japan. The Aflac U.S. segment provides accident, disability, cancer, critical illness, hospital indemnity, dental, vision, and life insurance products in the United States. The company sells its products through individual, independent corporate, and affiliated corporate agencies; banks; independent associates/career agents; and brokers. Aflac Incorporated was founded in 1955 and is based in Columbus, Georgia.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.